These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 303522)

  • 1. [Pharmacokinetic aspects of overdosage and intoxication with oral anticoagulant drugs (author's transl)].
    Jähnchen E; Meinertz T
    Arzneimittelforschung; 1977; 27(96):1849-56. PubMed ID: 303522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
    Haustein KO
    Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin K and the oral anticoagulant drugs.
    O'Reilly RA
    Annu Rev Med; 1976; 27():245-61. PubMed ID: 779597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of oral anticoagulants: implications for therapy.
    Shetty HG; Woods F; Routledge PA
    J Heart Valve Dis; 1993 Jan; 2(1):53-62. PubMed ID: 8269110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of anticoagulant poisoning--author's response.
    Roberge R
    Vet Hum Toxicol; 2001 Jun; 43(3):181. PubMed ID: 11383668
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacology of oral anticoagulants].
    Richter M; Markwardt F
    Z Gesamte Inn Med; 1979 Jan; 34(1):8-17. PubMed ID: 433362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine.
    Roberge RJ; Rao P; Miske GR; Riley TJ
    Vet Hum Toxicol; 2000 Dec; 42(6):351-3. PubMed ID: 11111942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
    van Aart L; Eijkhout HW; Kamphuis JS; Dam M; Schattenkerk ME; Schouten TJ; Ploeger B; Strengers PF
    Thromb Res; 2006; 118(3):313-20. PubMed ID: 16182346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factors influencing activity of oral anticoagulants. Interactions with drugs and food].
    Sawicka-Powierza J; Rogowska-Szadkowska D; Ołtarzewska AM; Chlabicz S
    Pol Merkur Lekarski; 2008 May; 24(143):458-62. PubMed ID: 18634396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions involving oral anticoagulants.
    O'Reilly RA
    Cardiovasc Clin; 1974; 6(2):23-41. PubMed ID: 4613460
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors.
    Hylek EM
    Semin Vasc Med; 2003 Aug; 3(3):271-8. PubMed ID: 15199460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemorrhagic complications during warfarin treatment].
    Gumulec J; Kessler P; Penka M; Klodová D; Králová S; Brejcha M; Wróbel M; Sumná E; Blatný J; Klaricová K; Riedlová P; Lasota Z
    Vnitr Lek; 2006 Mar; 52 Suppl 1():79-91. PubMed ID: 16637455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamics of the oral anticoagulant drugs.
    O'Reilly RA
    Prog Hemost Thromb; 1974; 2(0):175-213. PubMed ID: 4137288
    [No Abstract]   [Full Text] [Related]  

  • 16. [Factors influenceing the activity of oral anticoagulants].
    González Caamaño A; Díaz Barreiro LA
    Arch Inst Cardiol Mex; 1976; 46(1):59-68. PubMed ID: 938151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage.
    Holster IL; Hunfeld NG; Kuipers EJ; Kruip MJ; Tjwa ET
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):229-31. PubMed ID: 23799225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulant therapy: practical aspects of management.
    Brigden ML
    Postgrad Med; 1996 Jun; 99(6):81-4, 87-9, 93-4 passim. PubMed ID: 8668640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication.
    Caldwell JH; Greenberger NJ
    J Clin Invest; 1971 Dec; 50(12):2626-37. PubMed ID: 5129314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel anticoagulants and the future of anticoagulation.
    Garcia D
    Thromb Res; 2009; 123 Suppl 4():S50-5. PubMed ID: 19303505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.